How important is this differential over DM? "Anavex 2-73 also accelerates OPC maturation to OL".
IMO this is the relevant question related to Lisak data.
It has only minor importance and puts it with dozens of other drugs that do the same thing and most of which are generics. This is why the presentation will not affect the pps (i.e. NOT the short cabal) and why Biogen was never really interested. This study identified about 30 such compounds: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830134/
There are other studies and other compounds as well.
It's important in that A2-73 causes oligodendrocyte precursor cells to differentiate into mature oligodendrocytes. It takes a mature oligodendrocyte to create myelin. DM does not do this. I don't know of any other drug besides A2-73 that does this. Someone correct me if I am wrong. I suspect that BIIB is now working on finding out if these mature oligodendrocytes stimulated by A2-73 actually create new myelin. If they do, this is a big deal.